benzarone and Venous-Insufficiency

benzarone has been researched along with Venous-Insufficiency* in 3 studies

Trials

2 trial(s) available for benzarone and Venous-Insufficiency

Article	Year
[The behavior of blood clotting and its inhibitors under long term treatment with 5,6-benzo-alpha-pyrone (coumarin). Double blind study]. Arzneimittel-Forschung, 1985, Volume: 35, Issue:8 The analyses on hemostaseological variables are recorded in connection with blood tests in the course of a double-blind study in 41 patients suffering from chronic venous insufficiency of higher degrees of severity. They were treated in addition to compression measures with two active ingredients, a coumarin (5,6-benzo-alpha-pyrone)/troxerutin combination (Venalot Depot) (n = 20) or benzarone (n = 21) receiving 3 X 2 dragees daily for 6 weeks. Good clinical efficacy and the improvement of symptoms were observed together with almost no side-effects. The coagulation analysis showed no influence of the active principles on the global coagulation or the clotting factors and the inhibitors and factors of the fibrinolysis. In particular there was no phenprocoumon-like effect on the blood clotting system. Topics: Anticoagulants; Benzbromarone; Blood Coagulation; Clinical Trials as Topic; Coumarins; Double-Blind Method; Drug Combinations; Humans; Hydroxyethylrutoside; Partial Thromboplastin Time; Random Allocation; Rutin; Time Factors; Venous Insufficiency	1985
[Benzarone for leg edema caused by chronic venous insufficiency]. MMW, Munchener medizinische Wochenschrift, 1983, Apr-22, Volume: 125, Issue:16 Topics: Benzbromarone; Benzofurans; Chronic Disease; Clinical Trials as Topic; Edema; Female; Fibrinolytic Agents; Humans; Leg; Male; Venous Insufficiency	1983

Article

Year

[The behavior of blood clotting and its inhibitors under long term treatment with 5,6-benzo-alpha-pyrone (coumarin). Double blind study].

Arzneimittel-Forschung, 1985, Volume: 35, Issue:8

The analyses on hemostaseological variables are recorded in connection with blood tests in the course of a double-blind study in 41 patients suffering from chronic venous insufficiency of higher degrees of severity. They were treated in addition to compression measures with two active ingredients, a coumarin (5,6-benzo-alpha-pyrone)/troxerutin combination (Venalot Depot) (n = 20) or benzarone (n = 21) receiving 3 X 2 dragees daily for 6 weeks. Good clinical efficacy and the improvement of symptoms were observed together with almost no side-effects. The coagulation analysis showed no influence of the active principles on the global coagulation or the clotting factors and the inhibitors and factors of the fibrinolysis. In particular there was no phenprocoumon-like effect on the blood clotting system.

Topics: Anticoagulants; Benzbromarone; Blood Coagulation; Clinical Trials as Topic; Coumarins; Double-Blind Method; Drug Combinations; Humans; Hydroxyethylrutoside; Partial Thromboplastin Time; Random Allocation; Rutin; Time Factors; Venous Insufficiency

1985

[Benzarone for leg edema caused by chronic venous insufficiency].

MMW, Munchener medizinische Wochenschrift, 1983, Apr-22, Volume: 125, Issue:16

Topics: Benzbromarone; Benzofurans; Chronic Disease; Clinical Trials as Topic; Edema; Female; Fibrinolytic Agents; Humans; Leg; Male; Venous Insufficiency

1983

Other Studies

1 other study(ies) available for benzarone and Venous-Insufficiency

Article	Year
Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver, 1995, Volume: 15, Issue:1 We report three cases of severe hepatotoxicity related to benzarone, a benzofuran derivative. Our cases include a 35-year-old woman with (sub)fulminant hepatitis, a 67-year-old woman with macronodular cirrhosis, and a 68-year-old man with severe chronic active hepatitis and cirrhosis, with positivity of anti-smooth muscle antibodies. Two patients died. We stress the potential of benzarone to cause hepatotoxicity, which usually resembles severe chronic active hepatitis. Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone. Topics: Adult; Aged; Benzbromarone; Biopsy; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Fatal Outcome; Female; Fibrinolytic Agents; Hepatic Encephalopathy; Hepatitis, Chronic; Humans; Liver; Liver Cirrhosis; Male; Thrombophlebitis; Venous Insufficiency	1995

Article

Year

Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities.

Liver, 1995, Volume: 15, Issue:1

We report three cases of severe hepatotoxicity related to benzarone, a benzofuran derivative. Our cases include a 35-year-old woman with (sub)fulminant hepatitis, a 67-year-old woman with macronodular cirrhosis, and a 68-year-old man with severe chronic active hepatitis and cirrhosis, with positivity of anti-smooth muscle antibodies. Two patients died. We stress the potential of benzarone to cause hepatotoxicity, which usually resembles severe chronic active hepatitis. Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone.

Topics: Adult; Aged; Benzbromarone; Biopsy; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Fatal Outcome; Female; Fibrinolytic Agents; Hepatic Encephalopathy; Hepatitis, Chronic; Humans; Liver; Liver Cirrhosis; Male; Thrombophlebitis; Venous Insufficiency

1995